CAPTURE - Retrospective chart review (Riociguat)
Research type
Research Study
Full title
CAPTURE: Retrospective chart review of patients with PAH or inoperable / persistent / recurrent CTEPH who transition their PH treatment to Adempas
IRAS ID
202013
Contact name
Hellen McGoey
Contact email
Sponsor organisation
Bayer Plc
Duration of Study in the UK
0 years, 5 months, 30 days
Research summary
The term Pulmonary Hypertension (PH) refers to high blood pressure in the lungs. PH affects only the blood vessels in the lungs and the right side of the heart.
Pulmonary Arterial Hypertension (PAH) causes the walls of the arteries of the lungs to tighten and stiffen. In someone with PAH, the right side of the heart has to work harder to push blood through narrowed arteries in the lungs. PAH is a chronic and life changing disease that can lead to right heart failure if left untreated.
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a form of pulmonary hypertension caused by old blood clots in the lungs.
PAH and CTEPH are rare and life threatening diseases. Adempas® has shown to be effective and well tolerated in both indications in two randomised controlled trials and has since been approved by NICE to treat these conditions.
The aim of this study is to understand the treatment patterns in patients with PAH or inoperable / persistent /recurrent CTEPH after surgical treatment during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching.
It is planned to enrol a total of 80 patients from around the world.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
16/LO/0731
Date of REC Opinion
26 Apr 2016
REC opinion
Further Information Favourable Opinion